Showing posts with label ADHD. Show all posts
Showing posts with label ADHD. Show all posts

Wednesday, May 1, 2019

Mental Health

Today's News from the Lawmakers





CCHR Condemns FDA's Approval of Electricity-Zapping for 'ADHD' Kids
Source: The Ponder News
May 1, 2019
The Food and Drug Administration (FDA) has approved a device to zap a low-level electrical pulse through the forehead of 7-12 year olds as treatment for Attention Deficit Hyperactivity Disorder (ADHD).[1] But the mental health watchdog, Citizens Commission on Human Rights International (CCHR), says with concern that some psychiatrists have now turned to the FDA to approve a device that "electro-shocks children into docility."

Read more...



FDA permits marketing of first medical device for treatment of ADHD
Source: The Ponder News
April 22, 2019
The U.S. Food and Drug Administration has permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA.

Read more...



CCHR Condemns FDA's Approval of Electricity-Zapping for 'ADHD' Kids



by: Citizens Commission on Human Rights

Los Angeles, CA - May 1, 2019 - (The Ponder News) -- The Food and Drug Administration (FDA) has approved a device to zap a low-level electrical pulse through the forehead of 7-12 year olds as treatment for Attention Deficit Hyperactivity Disorder (ADHD).[1] But the mental health watchdog, Citizens Commission on Human Rights International (CCHR), says with concern that some psychiatrists have now turned to the FDA to approve a device that "electro-shocks children into docility."

The Monarch eTNS System device costs around $1,000, according to CNN. A patch placed on the forehead uses a 9-volt lithium battery stimulation that creates a "tingling sensation" on the skin between the eyebrows.[2] Jan Eastgate, president of CCHR International says, "With no FDA regulation of psychiatry,[3] this latest practice of zapping a lack of focus could send a wrong message to children. There are psychiatrists that would have them believe that electricity pulsing through their brain while they sleep may help control impulsive behavior." And pediatric neurologist, Dr. Fred Baughman advises parents that there is no proof that "ADHD" behavior has a medical or neurobiological cause.[4]

Recently, the FDA also cleared the usage of electroshock treatment—up to 460 volts of electricity through the brain—for adolescents aged 13 and above with "bipolar" disorder.[5] Yet according to the FD&C Act, the "FDA does not regulate the practice of medicine."[6] As such, "How psychiatrists administer electroshock is a free-for-all license for potentially committing 'mental euthanasia' on anyone they please, including children," Eastgate adds. She called on people to sign CCHR's petition to ban ECT

Freedom of Information requests CCHR filed in seven U.S. states reveal that psychiatrists are electroshocking kids aged five and younger.[7]

It is common for psychiatrists to say they don't know how ECT "works." In a petition to the FDA Commissioner in 2016, Constitutional attorney, Jonathon Emord noted, "How ECT 'works' and even if it works is highly disputed."[8]

Nor are there clinical studies proving safety and efficacy of ECT devices, Emord says.[9] Likewise, the exact mechanism of the Monarch eTNS System and its long term effects is unknown.[10]

As Forbes pointed out: "There are nearly a dozen neurostimulation devices on the market that claim to improve cognitive function by allowing you to zap your brain with a small electrical current. But just because you can now do this at home doesn't mean it's a good idea. ECT uses electrical current in the range of 600-1000 milliamps.... But you're welcome to zap your brain with a much lighter touch of roughly 1-2 milliamps from the comfort of your couch for anywhere between $99 and $800 dollars. That is, if you don't mind leaving the state of your brain up to chance."[11]

The marketing hype fed parents for this new device is likely to go something like this, Eastgate says: The "zapping" ADHD device is a "noninvasive treatment" and less risky than cocaine-like amphetamines or stimulants currently prescribed to treat "ADHD." This avoids drug side effects like anorexia, poor growth and cardiovascular problems.[12]

Jessica Baron, writing in Forbes noted, "While it's true that the [neurostimulation] electrodes don't penetrate your head, they must produce enough current to reach the brain in order to have any effect at all. Calling these products 'noninvasive' is merely a marketing technique and a misleading one if you ask me."[13]

Researchers do not understand the effects of long-term use of brain stimulation, but say that no brain region exists in isolation. Modulating one brain area may impact on other areas.[14]

Nick J. Davis Ph.D. from the Department of Psychology, Swansea University in the UK, explains that because the brain continues to develop until the age of 20, stimulation in children and adolescents would have a stronger impact.[15]

Davis said there is evidence that enhancing one aspect of cognition may be detrimental to other cognitive faculties. "There is also the worrying possibility that electrical stimulation of the skull may induce or inhibit bone growth, an issue of particular importance in children whose cranial bones are not yet fused. This latter possibility has not been explored in human volunteers in brain stimulation experiments," Davis wrote in 2014.[16]

Davis pleaded for "calm and caution" when opting for stimulation device use in children because serious effects of transcranial stimulation include seizure, mood changes or induction of hyper- or hypo-mania.

It's a "calm and caution" the FDA ignores, Eastgate alleges. The studies of the current ADHD device have been small—about 60 children, using the device or a placebo each night for four weeks only. [17] However, Carlos Peña, Ph.D., Director, Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health, said: "This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients."[18]

Dr. Peña also said that the FDA's Final Order on the ECT device classification provides information on its "safe and effective use" of ECT devices.[19]

Yet he was part of an FDA hearing in 2014 investigating the practice of aversive conditioning electrical devices to modify undesirable behavior.[20] In that case, the FDA recommended the device be banned, saying it subjected residents at the Judge Rotenberg Center in Massachusetts to "an unreasonable and substantial risk to public health."[21] For almost three decades the Center has been zapping its special-needs residents with a custom-designed electric shock machine that delivers charges of up to 41 milliamps—10 times the amperage used in most stun guns—to their legs, arms, hands, feet, fingers or torsos via electrodes on the skin.[22] In 2013, Juan Mendez, the UN's former special rapporteur on torture, concluded that the rights of students "subjected to electric shocks and physical means of restraints have been violated under the UN convention against torture."[23]

CCHR says ongoing dangerous decisions by the FDA warrant a Congressional investigation into children and others potentially being put at substantial health and mental risk.

“We do not have an independent, valid test for ADHD, and there is no data to indicate that ADHD is due to a brain malfunction.”— National Institute of Health (NIH) Consensus Statement

Monday, April 22, 2019

FDA permits marketing of first medical device for treatment of ADHD

======


======

by: U.S. Food and Drug Administration

Washington, D.C. - April 22, 2019 - (The Ponder News) -- The U.S. Food and Drug Administration has permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA.

“This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,” said Carlos Peña, Ph.D., director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health. “Today’s action reflects our deep commitment to working with device manufacturers to advance the development of pediatric medical devices so that children have access to innovative, safe and effective medical devices that meet their unique needs.”

ADHD is a common disorder that begins in childhood. Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior and very high levels of activity. The diagnosis of ADHD requires a comprehensive evaluation by a health care professional. For a person to receive a diagnosis of ADHD, the symptoms of inattention and/or hyperactivity-impulsivity must be chronic or long-lasting, impair the person’s functioning and cause the person to fall behind normal development for his or her age.

The Monarch eTNS System is intended to be used in the home under the supervision of a caregiver. The cell-phone sized device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrows, and should feel like a tingling sensation on the skin. The system delivers the low-level electrical stimulation to the branches of the trigeminal nerve, which sends therapeutic signals to the parts of the brain thought to be involved in ADHD. While the exact mechanism of eTNS is not yet known, neuroimaging studies have shown that eTNS increases activity in the brain regions that are known to be important in regulating attention, emotion and behavior.

The stimulation should feel like a tingling sensation on the skin, and the device should be used in the home under the supervision of a caregiver during periods of sleep. Clinical trials suggest that a response to eTNS may take up to 4 weeks to become evident. Patients should consult with their health care professional after four weeks of use to assess treatment effects.

The Monarch eTNS System’s efficacy in treating ADHD was shown in a clinical trial that compared eTNS as the sole treatment, or monotherapy, to a placebo device. A total of 62 children with moderate to severe ADHD were enrolled in the trial and used either the eTNS therapy each night or a placebo device at home for four weeks. The trial's primary endpoint was improvement on a clinician-administered ADHD Rating Scale, ADHD-RS. ADHD-RS scales are used to monitor severity and frequency of ADHD symptoms. A higher score is indicative of worsening symptoms. The ADHD-RS uses questions about the patient’s behavior, such as whether they have difficulty paying attention or regularly interrupt others. The trial showed that subjects using the eTNS device had statistically significant improvement in their ADHD symptoms compared with the placebo group. At the end of week four, the average ADHD-RS score in the active group decreased from 34.1 points at baseline to 23.4 points, versus a decrease from 33.7 to 27.5 points in the placebo group.

The most common side effects observed with eTNS use are: drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. No serious adverse events were associated with use of the device.

The Monarch eTNS System should not be used in children under seven years of age. It should not be used in patients with an active implantable pacemaker or with active implantable neurostimulators. Patients with body-worn devices such as insulin pumps should not use this device. The eTNS System should not be used in the presence of radio frequency energy such as magnetic resonance imaging (MRI), because it has not been tested in an MRI machine, or cell phones, because the phone’s low levels of electromagnetic energy may interrupt the therapy.

The FDA reviewed the Monarch eTNS System through the de novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Monarch eTNS System to NeuroSigma.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.